Bavarian Nordic AS
BV3
Company Profile
Business description
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
Contact
Philip Heymans Alle 3
Hellerup2900
DNKT: +45 33268383
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,861
Stocks News & Analysis
stocks
SpaceX is scaling AI infrastructure on earth, data centers in space might be next
Our view on the first results as a publicly traded company.
stocks
Investors too optimistic about overvalued ASX share
Upgraded first-half revenue guidance at the upper end of the previously announced range.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.10 | 39.50 | -0.44% |
| CAC 40 | 7,841.83 | 79.85 | -1.01% |
| DAX 40 | 25,517.12 | 127.92 | -0.50% |
| Dow JONES (US) | 52,856.09 | 360.21 | 0.69% |
| FTSE 100 | 10,740.43 | 12.45 | -0.12% |
| HKSE | 22,934.68 | 717.19 | -3.03% |
| NASDAQ | 26,702.86 | 278.04 | 1.05% |
| Nikkei 225 | 62,907.84 | 1,713.40 | -2.65% |
| NZX 50 Index | 13,746.84 | 14.45 | -0.11% |
| S&P 500 | 7,757.17 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,793.20 | 38.10 | -0.43% |
| SSE Composite Index | 3,658.03 | 55.00 | -1.48% |